share_log

LadRx (NASDAQ:CYTR) Coverage Initiated at StockNews.com

kopsource ·  Jan 28, 2023 17:43

StockNews.com started coverage on shares of LadRx (NASDAQ:CYTR – Get Rating) in a report published on Tuesday morning. The brokerage issued a hold rating on the stock.

LadRx Stock Performance

LadRx has a 12-month low of $0.05 and a 12-month high of $0.86. The stock's 50 day moving average is $0.09 and its 200-day moving average is $0.12.

Get LadRx alerts:

LadRx Company Profile

(Get Rating)

LadRx Corp. is a biopharmaceutical research and development company, which engages in the discovery, research, and clinical development of novel anti-cancer drug candidates. It focuses on developing the Linker Activated Drug Release (LADR) technology platform, a discovery engine to help create a pipeline of anti-cancer molecules that will avoid unacceptable systemic toxicity while delivering highly potent agents directly to the tumor.

See Also

  • Get a free copy of the StockNews.com research report on LadRx (CYTR)
  • MarketBeat Week in Review – 1/23- 1/27
  • Why Lucid Spiked Nearly 100% In One Day
  • Ride These Railroad Stocks for Growth and Income
  • ASML Sees Demand For Chips Rallying This Year, Boosts Sales View
  • KLA Corporation: Strength In A Troubled Semi-Market

Receive News & Ratings for LadRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LadRx and related companies with MarketBeat.com's FREE daily email newsletter.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment